phrykt

uniQure N.V. (QURE): who owns it and who trades it

As of Nov 16, 2026, QURE insiders reported 48 open-market sales worth $20M and no purchases in the last 12 months, with 90% of the sale value made under pre-set 10b5-1 plans. The largest seller was Matthew C Kapusta (CEO), with $12.9M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling uniQure

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns QURE

255 funds and institutions reported QURE shares worth $3.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Avoro Capital Advisors LLC with 10.7%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Avoro Capital Advisors LLC10.7%
JPMorgan Chase & Co7.7%
Rtw Investments, LP6.2%
State Street Corp4.6%
Aberdeen Group plc4.5%
California State Teachers Retirement System3.8%
BlackRock, Inc.3.0%
Orbimed Advisors LLC2.9%
Jane Street Group, LLC2.6%
Jennison Associates LLC2.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Avoro Capital Advisors LLC6.73M10.67%$310M+13%
JPMorgan Chase & Co4.87M7.72%$231M–
Rtw Investments, LP3.94M6.25%$182M+52%
State Street Corp2.90M4.60%$134M+28%
Aberdeen Group plc2.85M4.52%$131M-46%
California State Teachers Retirement System2.42M3.84%$52.6M–
BlackRock, Inc.1.88M2.98%$86.5M+8%
Orbimed Advisors LLC1.81M2.87%$83.3M-15%
Jane Street Group, LLC1.61M2.55%$74.2M+153%
Jennison Associates LLC1.56M2.48%$71.9M+27%
Boxer Capital Management, LLC1.50M2.38%$69.2M+127%
Goldman Sachs Group Inc1.48M2.34%$68M+17%
Two Sigma Investments, LP1.46M2.32%$67.3M-45%
Two Seas Capital LP1.44M2.29%$66.4M+11%
FMR LLC (Fidelity)1.27M2.01%$58.5M-27%
Mak Capital One LLC1.23M1.95%$56.7M+179%
Mpm Bioimpact LLC1.23M1.94%$56.5M-10%
Morgan Stanley1.07M1.69%$49.1M+191%
Assenagon Asset Management S.A.1.03M1.63%$47.3M+600%
Vestal Point Capital, LP935,0001.48%$43.1M+160%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, QURE insiders reported $0 of open-market purchases and $20M of sales. 90% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$20M
48 trades, 9 people
Sales under a 10b5-1 plan
90%
Share of sale value
Latest trade
Nov 6, 2026
Filed Nov 10, 2026

Purchases and sales by month

$15.6M$15.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 6, 2026David D. MeekDirectorSale plan9,080$21.25$193KForm 4
Jul 2, 2026Matthew C KapustaCEOSale plan7,600$45.89$349KForm 4
Jul 2, 2026Matthew C KapustaCEOSale plan4,282$45.43$195KForm 4
Jul 2, 2026Matthew C KapustaCEOSale plan9,200$44.43$409KForm 4
Jun 30, 2026Walid Abi-SaabChief Medical OfficerSale plan20,000$46.40$928KForm 4
Jun 30, 2026Walid Abi-SaabChief Medical OfficerSale plan10,000$46.46$465KForm 4
Jun 30, 2026Jack KayeDirectorSale plan17,060$46.43$792KForm 4
Jun 30, 2026Jack KayeDirectorSale plan4,107$46.49$191KForm 4
Jun 26, 2026Walid Abi-SaabChief Medical OfficerSale1,434$46.86$67.2KForm 4
Jun 25, 2026Matthew C KapustaCEOSale plan28,716$50.02$1.4MForm 4
Jun 24, 2026Matthew C KapustaCEOSale plan6,696$50.00$335KForm 4
Jun 18, 2026Matthew C KapustaCEOSale plan37,015$50.00$1.9MForm 4
Jun 18, 2026Matthew C KapustaCEOSale plan4,656$50.00$233KForm 4
Jun 17, 2026Matthew C KapustaCEOSale plan32,581$45.02$1.5MForm 4
Jun 17, 2026Matthew C KapustaCEOSale plan11,585$48.65$564KForm 4
Jun 17, 2026Matthew C KapustaCEOSale plan33,334$45.01$1.5MForm 4
Jun 17, 2026Matthew C KapustaCEOSale plan23,977$42.61$1MForm 4
Jun 17, 2026Matthew C KapustaCEOSale plan6,023$43.70$263KForm 4
Jun 17, 2026Matthew C KapustaCEOSale plan56,929$43.43$2.5MForm 4
Jun 17, 2026Madhavan BalachandranDirectorSale plan1,690$42.60$72KForm 4
Jun 17, 2026Madhavan BalachandranDirectorSale plan4,700$43.66$205KForm 4
Jun 17, 2026Madhavan BalachandranDirectorSale plan5,295$47.08$249KForm 4
Jun 17, 2026Jack KayeDirectorSale plan5,295$42.57$225KForm 4
Jun 15, 2026Madhavan BalachandranDirectorSale plan10,000$27.85$278KForm 4
Jun 15, 2026Jeannette PottsChief Legal OfficerSale5,237$27.67$145KForm 4
Jun 11, 2026David D. MeekDirectorSale1,993$27.06$53.9KForm 4
Jun 11, 2026Robert GutDirectorSale plan2,726$27.06$73.8KForm 4
Jun 11, 2026Kylie O'KeefeChief Customer & Strat OSale15,936$27.06$431KForm 4
Jun 10, 2026Robert GutDirectorSale plan2,645$26.07$69KForm 4
Jun 10, 2026Robert GutDirectorSale plan3,127$26.03$81.4KForm 4
Jun 10, 2026Robert GutDirectorSale plan1,780$26.05$46.4KForm 4
Jun 3, 2026Jack KayeDirectorSale plan2,645$30.01$79.4KForm 4
May 8, 2026Walid Abi-SaabChief Medical OfficerSale plan25,000$25.10$628KForm 4
May 8, 2026Walid Abi-SaabChief Medical OfficerSale plan20,000$25.00$500KForm 4
Mar 4, 2026Matthew C KapustaCEOSale14,581$9.06$132KForm 4
Mar 4, 2026Walid Abi-SaabChief Medical OfficerSale808$9.06$7.3KForm 4
Mar 4, 2026Jeannette PottsChief Legal OfficerSale3,412$9.06$30.9KForm 4
Mar 4, 2026Christian KlemtCFOSale12,000$9.06$109KForm 4
Mar 2, 2026Matthew C KapustaCEOSale34,437$9.95$343KForm 4
Mar 2, 2026Christian KlemtCFOSale12,532$9.95$125KForm 4
Mar 2, 2026Jeannette PottsChief Legal OfficerSale8,578$9.95$85.4KForm 4
Mar 2, 2026Walid Abi-SaabChief Medical OfficerSale1,660$9.95$16.5KForm 4
Feb 25, 2026Matthew C KapustaCEOSale12,378$23.86$295KForm 4
Feb 25, 2026Christian KlemtCFOSale6,217$23.86$148KForm 4
Jan 12, 2026Robert GutDirectorSale plan17,310$24.39$422KForm 4
Jan 12, 2026Robert GutDirectorSale plan7,803$25.09$196KForm 4
Jan 12, 2026Robert GutDirectorSale plan500$25.03$12.5KForm 4
Jan 9, 2026Jack KayeDirectorSale plan6,390$27.28$174KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Matthew C KapustaCEO, Managing Director, Director–$12.9MJul 2, 2026
Walid Abi-SaabChief Medical Officer–$2.6MJun 30, 2026
Jack KayeDirector–$1.5MJun 30, 2026
Robert GutDirector–$901KJun 11, 2026
Madhavan BalachandranDirector–$805KJun 17, 2026
Kylie O'KeefeChief Customer & Strat Officer–$431KJun 11, 2026
Christian KlemtChief Financial Officer–$382KMar 4, 2026
Jeannette PottsChief Legal Officer–$261KJun 15, 2026
David D. MeekDirector–$247KNov 6, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

QURE short interest

High short interest. 12.3% of QURE shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 17%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.51M QURE shares were sold short, 12.3% of the shares outstanding, down 2.5% from the report before. At the average daily volume of 1.33M shares, buying them all back would take about 6.4 trading days (days to cover).

Shares short, % of all shares

12.3%May 15Oct 3019.7%

Days to cover

6.4May 15Oct 3011.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.51M12.26%-3%1.33M6.4
Oct 15, 20268.73M12.58%+0%2.27M3.8
Sep 30, 20268.72M12.56%-12%4.49M1.9
Sep 15, 20269.92M14.30%+0%1.22M8.1
Aug 31, 20269.87M14.24%-8%1.05M9.4
Aug 14, 202610.77M15.53%+1%1.09M9.8
Jul 31, 202610.68M15.40%+3%1.57M6.8
Jul 15, 202610.37M16.44%-10%1.46M7.1
Jun 30, 202611.49M18.23%-3%4.47M2.6
Jun 15, 202611.81M18.72%+6%1.44M8.2
May 29, 202611.10M17.60%+8%1.23M9.0
May 15, 202610.30M16.33%-5%2.57M4.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

uniQure company events

uniQure filed 15 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Nov 2, 2026AnnouncementThe Company announced the FDA has accepted for review the BLA for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s disease submitted under the Accelerated Approval pathway. Filing
  3. Sep 29, 2026AnnouncementShared information with investors. Filing
  4. Sep 2, 2026AnnouncementShared information with investors. Filing
  5. Jul 29, 2026ResultsReleased financial results. Filing
  6. Jun 24, 2026AgreementUniQure N.V. entered into an underwriting agreement with Leerink Partners LLC, as representative of the several underwriters named therein, relating to an underwritten public offering of 4,945,055 of the Company’s ordinary shares, at a price to the public of $ 45.50 per ordinary share. Filing
  7. Jun 22, 2026AnnouncementThe Company announced preliminary data on the first cohort in the Company’s Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy. Filing
  8. Jun 17, 2026AnnouncementUniQure N.V. issued a press release announcing its plan to submit its Biologic License Application for AMT-130 in Huntington’s Disease during the third quarter of 2026. Filing
  9. Jun 15, 2026LeadershipAs described in Item 5.07, on June 10, 2026, at the 2026 Annual General Meeting of Shareholders, the shareholders of uniQure N.V. approved an amendment to the Company’s Amended and Restated 2014 Share Incentive Plan to increase the number of ordinary shares reserved for issuance thereunder. Filing
  10. May 5, 2026ResultsReleased financial results. Filing
  11. Apr 30, 2026AnnouncementShared information with investors. Filing
  12. Mar 2, 2026ResultsReleased financial results. Filing
  13. Jan 13, 2026AnnouncementShared information with investors. Filing
  14. Jan 9, 2026AnnouncementShared information with investors. Filing
  15. Dec 4, 2025AnnouncementThe Company announced that the Company received final meeting minutes from the U.S. Food and Drug Administration regarding a pre-Biologics License Application meeting held on October 29, 2025 to discuss the application for AMT-130, an investigational gene therapy for Huntington’s disease. ​ In the… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

uniQure financials

Famous investors that hold QURE

4 of the 50 well-known investors we track reported holding QURE in their latest 13F filing. The largest position is Ken Griffin's, worth $17.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026718,875$17.4M0.0%-21%
Steve Cohen · Point72 Asset ManagementQ3 2026330,665$8M0.0%-45%
Israel Englander · Millennium ManagementQ3 2026181,618$4.4M0.0%-47%
Paul Tudor Jones · Tudor Investment CorpQ3 202699,263$2.4M0.0%-70%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named QURE in the last 120 days.

FiledHolderFormStake
Oct 16, 2026JPMORGAN CHASE & CO.13G/A8.5%
Oct 16, 2026JPMORGAN CHASE & CO.13G/A8.5%

Questions about uniQure N.V. (QURE) stock

Who owns the most QURE stock?

The largest reported owner of uniQure N.V. (QURE) is Avoro Capital Advisors LLC, with 10.7% of the company. In total, 255 funds and institutions reported holding QURE at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are QURE insiders buying or selling?

In the last 12 months, QURE insiders reported no open-market purchases and 48 sales worth $20M. The latest trade was on Nov 6, 2026. See every trade.

What is the short interest in QURE?

As of Oct 30, 2026, 8.51M QURE shares were sold short, 12.3% of the shares outstanding, down 2.5% from the report before. At the average daily volume of 1.33M shares, buying them all back would take about 6.4 trading days (days to cover). See the history.

Which famous investors hold QURE?

4 of the 50 well-known investors we track reported QURE in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $17.4M. See all holders.

Executive pay

uniQure's chief executive was paid a total of $3.3M for the year ended Dec 31, 2025, up 7% from $3.1M the year before. In the last 12 months, uniQure's executives and directors bought no stock on the open market and sold $20M.

Chief executive, total pay$3.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$7.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.9MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.